The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue SUPPL. 2, 2011, Pages 10871-10877

  Read, Andrew F ^a,b   Day, Troy ^c   Huijben, Silvie ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c QUEEN S UNIVERSITY   (Canada)

Author keywords

Antibiotic resistance; Evolutionary medicine; Long course chemotherapy; Patient treatment regimens; Plasmodium

Indexed keywords

ANTIMALARIAL AGENT;

CHEMOTHERAPY; CONFERENCE PAPER; DISEASE TRANSMISSION; DRUG RESISTANCE; GENETIC RESISTANCE; GENETIC VARIABILITY; HEALTH CARE COST; HUMAN; MALARIA; NONHUMAN; PATIENT CARE; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; SOCIAL INTERACTION; TREATMENT FAILURE; TREATMENT RESPONSE;

EID: 79960648350     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1100299108     Document Type: Article

References (98)

1. Owens RC, Jr. (2008) Antimicrobial stewardship: Concepts and strategies in the 21st century. Diagn Microbiol Infect Dis 61:110-128.
2. Spellberg B, et al.; Infectious Diseases Society of America (2008) The epidemic of antibiotic-resistant infections: A call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 46:155-164.
3. American Academy of Microbiology (2009) Antibiotic Resistance: An Ecological Perspective on an Old Problem (American Academy of Microbiology, Washington, DC). Available at http://academy.asm.org/index.php/colloquium- program/environmental-microbiology-ecology-a-evolution-/190-antibiotic- resistance-an-ecological-perspective-on-an-old-problem-september-2009-b. Accessed February 12, 2011.
4. World Health Organization (2010) Guidelines for the Treatment of Malaria (World Health Organization, Geneva), 2nd Ed. Available at http://www.who.int/ malaria/publications/atoz/9789241547925/en/index.html. Accessed February 5, 2011.
5. zur Wiesch PA, Kouyos R, Engelstädter J, Regoes RR, Bonhoeffer S (2011) Population biological principles of drug-resistance evolution in infectious diseases. Lancet Infect Dis 11:236-247.
6. Maynard Smith J (1989) Evolutionary Genetics (Oxford Univ Press, Oxford).
7. Foster KR, Grundmann H (2006) Do we need to put society first? The potential for tragedy in antimicrobial resistance. PLoS Med 3:e29.
8. Hyde JE (2005) Drug-resistant malaria. Trends Parasitol 21:494-498.
9. Roll Back Malaria (2008) The Global Malaria Action Plan (Roll Back Malaria Partnership). Available at http://www.rbm.who.int/gmap/gmap.pdf. Accessed November 28, 2008.
10. World Health Organization (2006) Guidelines for the Treatment of Malaria (World Health Organization, Geneva).
11. Read AF, Taylor LH (2001) The ecology of genetically diverse infections. Science 292:1099-1102. (Pubitemid 32440920)
12. Day KP, Koella JC, Nee S, Gupta S, Read AF (1992) Population genetics and dynamics of Plasmodium falciparum: An ecological view. Parasitology 104(Suppl):S35-S52.
13. Arnot D (1998) Clone multiplicity of Plasmodium falciparum infections in individuals exposed to variable levels of disease transmission. Trans R Soc Trop Med Hyg 92:580-585.
14. Babiker HA, Ranford-Cartwright LC, Walliker D (1999) The epidemiology of multiple Plasmodium falciparum infections. 3. Genetic structure and dynamics of Plasmodium falciparum infections in the Kilombero region of Tanzania. Trans R Soc Trop Med Hyg 93(Suppl 1):11-14.
15. Smith T, Felger I, Tanner M, Beck H-P (1999) The epidemiology of multiple Plasmodium falciparum infections. 11. Premunition in Plasmodium falciparum infection: Insight from the epidemiology of multiple infections. Trans R Soc Trop Med Hyg 93(Suppl 1):59-64.
16. Bruce MC, et al. (2000) Cross-species interactions between malaria parasites in humans. Science 287:845-848. (Pubitemid 30084325)
17. Jafari S, Le Bras J, Bouchaud O, Durand R (2004) Plasmodium falciparum clonal population dynamics during malaria treatment. J Infect Dis 189:195-203. (Pubitemid 38147242)
18. Juliano JJ, Kwiek JJ, Cappell K, Mwapasa V, Meshnick SR (2007) Minority-variant pfcrt K76T mutations and chloroquine resistance, Malawi. Emerg Infect Dis 13:872-877.
19. Juliano JJ, et al. (2010) Exposing malaria in-host diversity and estimating population diversity by capture-recapture using massively parallel pyrosequencing. Proc Natl Acad Sci USA 107:20138-20143.
20. McCollum AM, Basco LK, Tahar R, Udhayakumar V, Escalante AA (2008) Hitchhiking and selective sweeps of Plasmodium falciparum sulfadoxine and pyrimethamine resistance alleles in a population from central Africa. Antimicrob Agents Chemother 52:4089-4097.
21. Zhong DB, et al. (2008) Molecular epidemiology of drug-resistant malaria in western Kenya highlands. BMC Infect Dis 8:105.
22. Owusu-Agyei S, et al. (2009) Epidemiology of malaria in the forest-savanna transitional zone of Ghana. Malar J 8:220.
23. Daubersies P, et al. (1996) Rapid turnover of Plasmodium falciparum populations in asymptomatic individuals living in a high transmission area. Am J Trop Med Hyg 54:18-26. (Pubitemid 26045727)
24. Mercereau-Puijalon O (1996) Revisiting host/parasite interactions: Molecular analysis of parasites collected during longitudinal and cross-sectional surveys in humans. Parasite Immunol 18:173-180.
25. Hastings IM (2003) Malaria control and the evolution of drug resistance: An intriguing link. Trends Parasitol 19:70-73.
26. Talisuna AO, et al. (2003) Intensity of transmission and spread of gene mutations linked to chloroquine and sulphadoxine-pyrimethamine resistance in falciparum malaria. Int J Parasitol 33:1051-1058. (Pubitemid 37297533)
27. Talisuna AO, et al. (2006) Malaria transmission intensity and the rate of spread of chloroquine resistant Plasmodium falciparum: Why have theoretical models generated conflicting results? Infect Genet Evol 6:241-248.
28. Färnert A (2008) Plasmodium falciparum population dynamics: Only snapshots in time? Trends Parasitol 24:340-344.
29. Orjuela-Sánchez P, et al. (2009) Population dynamics of genetically diverse Plasmodium falciparum lineages: Community-based prospective study in rural Amazonia. Parasitology 136:1097-1105.
30. Baliraine FN, et al. (2010) A cohort study of Plasmodium falciparum infection dynamics in Western Kenya Highlands. BMC Infect Dis 10:283.
31. Harrington WE, et al. (2009) Competitive facilitation of drug-resistant Plasmodium falciparum malaria parasites in pregnant women who receive preventive treatment. Proc Natl Acad Sci USA 106:9027-9032.
32. Jarra W, Brown KN (1985) Protective immunity to malaria: Studies with cloned lines of Plasmodium chabaudi and P. berghei in CBA/Ca mice. I. The effectiveness and inter- and intra-species specificity of immunity induced by infection. Parasite Immunol 7: 595-606.
33. Taylor LH, Walliker D, Read AF (1997) Mixed-genotype infections of malaria parasites: Within-host dynamics and transmission success of competing clones. Proc R Soc B 264:927-935.
34. Taylor LH, Walliker D, Read AF (1997) Mixed-genotype infections of the rodent malaria Plasmodium chabaudi are more infectious to mosquitoes than single-genotype infections. Parasitology 115:121-132. (Pubitemid 27334566)
35. Taylor LH, Read AF (1998) Determinants of transmission success of individual clones from mixed-clone infections of the rodent malaria parasite, Plasmodium chabaudi. Int J Parasitol 28:719-725. (Pubitemid 28266901)
36. de Roode JC, Culleton R, Bell AS, Read AF (2004) Competitive release of drug resistance following drug treatment of mixed Plasmodium chabaudi infections. Malar J 3:33.
37. de Roode JC, Culleton R, Cheesman SJ, Carter R, Read AF (2004) Host heterogeneity is a determinant of competitive exclusion or coexistence in genetically diverse malaria infections. Proc R Soc B 271:1073-1080. (Pubitemid 38657405)
38. de Roode JC, Helinski MEH, Anwar MA, Read AF (2005) Dynamics of multiple infection and within-host competition in genetically diverse malaria infections. Am Nat 166:531-542. (Pubitemid 41587941)
39. de Roode JC, et al. (2005) Virulence and competitive ability in genetically diverse malaria infections. Proc Natl Acad Sci USA 102:7624-7628.
40. de Roode JC, Read AF, Chan BHK, Mackinnon MJ (2003) Rodent malaria parasites suffer from the presence of conspecific clones in three-clone Plasmodium chabaudi infections. Parasitology 127:411-418. (Pubitemid 37452536)
41. Raberg L, et al. (2006) The role of immune-mediated apparent competition in genetically diverse malaria infections. Am Nat 168:41-53. (Pubitemid 44100596)
42. Wargo AR, Huijben S, de Roode JC, Shepherd J, Read AF (2007) Competitive release and facilitation of drug-resistant parasites after therapeutic chemotherapy in a rodent malaria model. Proc Natl Acad Sci USA 104:19914-19919.
43. Huijben S, et al. (2010) Chemotherapy, within-host ecology and the fitness of drug-resistant malaria parasites. Evolution 64:2952-2968.
44. Pollitt LC, et al. (2011) Competition and the evolution of reproductive restraint in malaria parasites. Am Nat 177:358-367.
45. Riley MA, Gordon DM (1999) The ecological role of bacteriocins in bacterial competition. Trends Microbiol 7:129-133.
46. Hellriegel B (1992) Modelling the immune response to malaria with ecological concepts: Short-term behaviour against long-term equilibrium. Proc R Soc B 250:249-256.
47. Yap GS, Stevenson MM (1994) Blood transfusion alters the course and outcome of Plasmodium chabaudi AS infection in mice. Infect Immun 62:3761-3765. (Pubitemid 24264317)
48. Hetzel C, Anderson RM (1996) The within-host cellular dynamics of bloodstage malaria: Theoretical and experimental studies. Parasitology 113:25-38. (Pubitemid 26228365)
49. Haydon DT, Matthews L, Timms R, Colegrave N (2003) Top-down or bottom-up regulation of intra-host blood-stage malaria: Do malaria parasites most resemble the dynamics of prey or predator? Proc R Soc B 270:289-298.
50. Antia R, Yates A, de Roode JC (2008) The dynamics of acute malaria infections. I. Effect of the parasite's red blood cell preference. Proc Biol Sci 275:1449-1458.
51. Mideo N, et al. (2008) Understanding and predicting strain-specific patterns of pathogenesis in the rodent malaria Plasmodium chabaudi. Am Nat 172:214-238.
52. Miller MR, Råberg L, Read AF, Savill NJ (2010) Quantitative analysis of immune response and erythropoiesis during rodent malaria infection. PLoS Comput Biol 6:e1000946.
53. Kochin BF, Yates AJ, de Roode JC, Antia R (2010) On the control of acute rodent malaria infections by innate immunity. PLoS ONE 5:e10444.
54. Mota MM, Brown KN, Do Rosário VE, Holder AA, Jarra W (2001) Antibody recognition of rodent malaria parasite antigens exposed at the infected erythrocyte surface: Specificity of immunity generated in hyperimmune mice. Infect Immun 69:2535-2541. (Pubitemid 32239727)
55. Walliker D, Hunt P, Babiker H (2005) Fitness of drug-resistant malaria parasites. Acta Trop 94:251-259. (Pubitemid 40723640)
56. Babiker HA, Hastings IM, Swedberg G (2009) Impaired fitness of drug-resistant malaria parasites: Evidence and implication on drug-deployment policies. Expert Rev Anti Infect Ther 7:581-593.
57. Hastings IM, Donnelly MJ (2005) The impact of antimalarial drug resistance mutations on parasite fitness, and its implications for the evolution of resistance. Drug Resist Updat 8:43-50. (Pubitemid 40797955)
58. Hastings IM (1997) A model for the origins and spread of drug resistance. Parasitology 115:133-141.
59. Mackinnon MJ, Hastings IM (1998) The evolution of multiple drug resistance in malaria parasites. Trans R Soc Trop Med Hyg 92:188-195. (Pubitemid 28202428)
60. Hastings IM, D'Alessandro U (2000) Modelling a predictable disaster: The rise and spread of drug-resistant malaria. Parasitol Today 16:340-347. (Pubitemid 30460031)
61. Hastings IM (2006) Complex dynamics and stability of resistance to antimalarial drugs. Parasitology 132:615-624.
62. Mackinnon MJ (2005) Drug resistance models for malaria. Acta Trop 94:207-217.
63. White NJ (2004) Antimalarial drug resistance. J Clin Invest 113:1084-1092.
64. Hastings IM, Watkins WM (2006) Tolerance is the key to understanding antimalarial drug resistance. Trends Parasitol 22:71-77. (Pubitemid 43145866)
65. Stepniewska K, White NJ (2008) Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob Agents Chemother 52:1589-1596. (Pubitemid 351614647)
66. World Health Organization (2010) World Malaria Report (World Health Organization, Geneva). Available at http://www.who.int/malaria/world-malaria- report-2010/en/index.html. Accessed February 12, 2011.
67. Pongtavornpinyo W, et al. (2009) Probability of emergence of antimalarial resistance in different stages of the parasite life cycle. Evol Appl 2:52-61.
68. Hastings IM (2011) How artemisinin-containing combination therapies slow the spread of antimalarial drug resistance. Trends Parasitol 27:67-72.
69. Levin BR, Perrot V, Walker N (2000) Compensatory mutations, antibiotic resistance and the population genetics of adaptive evolution in bacteria. Genetics 154:985-997. (Pubitemid 30140690)
70. Hastings IM (2011) Why we should effectively treat malaria. Trends Parasitol 27:51-52.
71. Read AF, Huijben S (2009) Evolutionary biology and the avoidance of antimicrobial resistance. Evol Appl 2:40-51.
72. Goncalves BPA, Paul REL (2011) Sub-clearance treatment to slow malaria drug resistance? Trends Parasitol 27:50-51.
73. Brown EM, Nathwani D (2005) Antibiotic cycling or rotation: A systematic review of the evidence of efficacy. J Antimicrob Chemother 55:6-9. (Pubitemid 40192608)
74. Martínez JA, et al. (2006) Comparison of antimicrobial cycling and mixing strategies in two medical intensive care units. Crit Care Med 34:329-336.
75. Smith RL, et al. (2008) Reduction in rates of methicillin-resistant Staphylococcus aureus infection after introduction of quarterly linezolid-vancomycin cycling in a surgical intensive care unit. Surg Infect (Larchmt) 9:423-431.
76. Penilla RP, et al. (2007) Cytochrome P450-based resistance mechanism and pyrethroid resistance in the field Anopheles albimanus resistance management trial. Pestic Biochem Physiol 89:111-117. (Pubitemid 47334722)
77. Gandon S, Day T (2009) Evolutionary epidemiology and the dynamics of adaptation. Evolution 63:826-838.
78. World Health Organization (2011) Global Plan for Artemisinin Resistance Containment (World Health Organization, Geneva). Available at http://www.who.int/malaria/publications/atoz/9789241500838/en/index.html. Accessed February 12, 2011.
79. Cravo P, Culleton R, Hunt P, Walliker D, Mackinnon MJ (2001) Antimalarial drugs clear resistant parasites from partially immune hosts. Antimicrob Agents Chemother 45:2897-2901. (Pubitemid 32906689)
80. Rice LB (2008) The Maxwell Finland Lecture: For the duration-rational antibiotic administration in an era of antimicrobial resistance and Clostridium difficile. Clin Infect Dis 46:491-496.
81. Rice LB (2008) Bacteria by the book: Response. Science 322:853-854.
82. Taubes G (2008) The bacteria fight back. Science 321:356-361.
83. Ehrlich P (1913) Address in pathology on chemotherapeutics: Scientific principles, methods, and results. Lancet 182:445-451.
84. Luciani F, Sisson SA, Jiang HL, Francis AR, Tanaka MM (2009) The epidemiological fitness cost of drug resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 106:14711-14715.
85. Wootton JC, et al. (2002) Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum. Nature 418:320-323. (Pubitemid 34790681)
86. Talisuna AO, Bloland P, D'Alessandro U (2004) History, dynamics, and public health importance of malaria parasite resistance. Clin Microbiol Rev 17:235-254. (Pubitemid 38120936)
87. Roper C, et al. (2004) Intercontinental spread of pyrimethamine-resistant malaria. Science 305:1124. (Pubitemid 39100317)
88. Levin BR, Rozen DE (2006) Non-inherited antibiotic resistance. Nat Rev Microbiol 4:556-562. (Pubitemid 43905615)
89. Dye C (2009) Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis. Nat Rev Microbiol 7:81-87.
90. Prichard R, Tait A (2001) The role of molecular biology in veterinary parasitology. Vet Parasitol 98:169-194. (Pubitemid 32539275)
91. West SA, Griffin AS, Gardner A, Diggle SP (2006) Social evolution theory for microorganisms. Nat Rev Microbiol 4:597-607. (Pubitemid 44317022)
92. Lipsitch M, Samore MH (2002) Antimicrobial use and antimicrobial resistance: A population perspective. Emerg Infect Dis 8:347-354. (Pubitemid 34415194)
93. Vonberg RP, et al. (2008) Infection control measures to limit the spread of Clostridium difficile. Clin Microbiol Infect 14(Suppl 5):2-20.
94. Gatenby RA (2009) A change of strategy in the war on cancer. Nature 459:508-509.
95. Gatenby RA, Silva AS, Gillies RJ, Frieden BR (2009) Adaptive therapy. Cancer Res 69:4894-4903.
96. Read AF, Lynch PA, Thomas MB (2009) How to make evolution-proof insecticides for malaria control. PLoS Biol 7:e1000058.
97. Koella JC, Lynch PA, Thomas MB, Read AF (2009) Towards evolution-proof malaria control with insecticides. Evol Appl 2:469-480.
98. Gourley SA, Liu R, Wu J (2011) Slowing the evolution of insecticide resistance in mosquitoes: A mathematical model. Proc R Soc A, 10.1098/rspa.2010.0413.